Education
About Us
Working with TipRanks
Follow Us
Soleno Therapeutics (SLNO)
:SLNO
SLNO Stock Chart & Stats
$67.16
-$1.55(-3.35%)
At close: 4:00 PM EST
$67.16
-$1.55(-3.35%)
Day’s Range― - ―
52-Week Range$41.50 - $90.32
Previous CloseN/A
Volume118.06K
Average Volume (3M)1.67M
Market Cap
$3.68B
Enterprise Value$4.00B
Total Cash (Recent Filing)$286.84M
Total Debt (Recent Filing)$52.77M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Nov 04, 2025EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding53,145,008
10 Day Avg. Volume1,271,169
30 Day Avg. Volume1,670,434
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue122.34
Enterprise Value/Gross Profit125.01
Enterprise Value/Ebitda-22.34
Forecast
1Y Price Target
$119.82Price Target Upside78.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Future Market PotentialThere is upside potential from the expected launch in the EU5, with projected sales higher than consensus estimates.
Market PenetrationSLNO's early launch execution has been strong, with rapid penetration in the US market and a transition to profitability and cash flow generation.
Revenue GrowthVykat XR generated $33MM of net revenue during its first partial quarter of launch, representing a remarkable beat that speaks to both the urgent need for a hyperphagia treatment and Soleno management's commercial prowess.
Bears Say
Safety ConcernsInvestors have raised concerns about Vykat XR’s safety profile due to potential edema/pulmonary edema while on treatment.
Soleno Therapeutics News
SLNO FAQ
What was Soleno Therapeutics’s price range in the past 12 months?
Soleno Therapeutics lowest stock price was $41.50 and its highest was $90.32 in the past 12 months.
What is Soleno Therapeutics’s market cap?
Soleno Therapeutics’s market cap is $3.68B.
When is Soleno Therapeutics’s upcoming earnings report date?
Soleno Therapeutics’s upcoming earnings report date is Nov 04, 2025 which is in 3 days.
How were Soleno Therapeutics’s earnings last quarter?
Soleno Therapeutics released its earnings results on Aug 06, 2025. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.453 by $0.363.
Is Soleno Therapeutics overvalued?
According to Wall Street analysts Soleno Therapeutics’s price is currently Undervalued.
Does Soleno Therapeutics pay dividends?
Soleno Therapeutics does not currently pay dividends.
What is Soleno Therapeutics’s EPS estimate?
Soleno Therapeutics’s EPS estimate is 0.06.
How many shares outstanding does Soleno Therapeutics have?
Soleno Therapeutics has 53,145,008 shares outstanding.
What happened to Soleno Therapeutics’s price movement after its last earnings report?
Soleno Therapeutics reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.453. Following the earnings report the stock price went down -3.055%.
Which hedge fund is a major shareholder of Soleno Therapeutics?
Currently, no hedge funds are holding shares in SLNO
Soleno Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$119.82 (78.41% Upside)
$119.82 (78.41% Upside)
Blogger Sentiment
Bearish
SLNO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 22.0%
Last 30 Days ▲ 22.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.97%
12-Months-Change
Fundamentals
Return on Equity
-69.53%
Trailing 12-Months
Asset Growth
9.26%
Trailing 12-Months
Company Description
Soleno Therapeutics
Soleno Therapeutics, Inc. (SLNO) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's primary product candidate is DCCR (Diazoxide Choline Controlled Release) tablets, which are in late-stage clinical development for the treatment of Prader-Willi Syndrome (PWS), a complex genetic neurobehavioral and metabolic disorder. Soleno is committed to improving the lives of patients with rare diseases through innovative solutions and therapies.
SLNO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a highly positive sentiment with the successful launch and strong initial uptake of Vykat XR. The company's robust financial position and broad payer coverage further underscore the positive outlook. However, there are some uncertainties regarding future revenue streams and the upcoming challenges in the European market.View all SLNO earnings summariesSLNO Stock 12 Month Forecast
Average Price Target
$119.82
▲(78.41% Upside)
Technical Analysis
Ownership Overview
10.06% Insiders
25.37% Mutual Funds
0.02% Other Institutional Investors
53.66% Public Companies and
Individual Investors